[Pharmacologic treatment of heart failure: general principle].
Sasayama
Shigetake
S
Doshisha University, Heart Bio-Mechanics Center, Daijukai, Hospital.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000145:classification / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D012307:Risk Factors; D012720:Severity of Illness Index; D014665:Vasodilator Agents / Q000627:therapeutic use; D020257:Ventricular Remodeling
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004071:Digitalis Glycosides; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D014665:Vasodilator Agents